Funding for this research was provided by:
Rare Kidney Stone Consortium (5U54DK083908-05)
NIH Center Grant (P30 ES 020957)
NIH Cancer Center Support Grant (P30 CA 022453)
NIH Shared Instrumentation Grant (S10 OD 010700)
Text and Data Mining valid from 2018-12-05
Received: 11 September 2018
Accepted: 23 November 2018
First Online: 5 December 2018
Compliance with ethical standards
: D.S. Goldfarb is a consultant for Retrophin and is owner of Ravine Group. The rest of the authors have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The urine was obtained for routine urinalysis for clinical care, and would have then been discarded; it was sent to the proteomics laboratory without any personal health identification information. Under these circumstances, analysis of the urine is not considered human subjects research. and therefore informed consent was not required from the participants included in the study.